Bacil Pharma Share Price

Bacil Pharma Limited is a micro‑cap pharmaceutical company with a chequered history, engaged in the manufacture and sale of pharmaceutical, medicinal, and botanical products since its incorporation in 1987. The company has a manufacturing plant in Lote‑Parshuram, which also has a facility for herbal extracts and drug intermediates. The Bacil Pharma share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

Market sentiment around the Bacil Pharma stock price often mirrors shifts in investor perception regarding the company’s ability to reduce accumulated losses and generate consistent revenue from its drug manufacturing operations. Factors such as the pace of new business initiatives, quality of financial reporting, and broader market interest in penny stocks influence near‑term valuation and medium‑term earnings forecasts. All these factors must be closely monitored to have an idea about the Bacil Pharma share price movements. 

The Bacil Pharma live share price provides real‑time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, board meeting outcomes, and sector news. Constant monitoring of Bacil Pharma live price helps observe short‑term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Bacil Pharma share price today helps investors understand real‑time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short‑term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. The Bacil Pharma stock price is influenced by the company’s financial health and industry trends, making it a key metric for potential investors. Bacil Pharma share price movements are closely tied to the pharmaceutical sector’s performance. 

Bacil Pharma Limited Company Fundamentals 

A. Company Background

Bacil Pharma Limited was incorporated in 1987. The company’s registered office is located in Mumbai, Maharashtra, India. Bacil Pharma is engaged in the manufacture and sale of pharmaceutical, medicinal, and botanical products. Its manufacturing plant is located in Lote‑Parshuram, which also has a facility for herbal extracts and drug intermediates. The company was founded on May 8, 1987 and is headquartered in Mumbai, India. As a micro‑cap entity, it operates in a highly competitive environment within the pharmaceutical sector. The company is listed on the Bombay Stock Exchange (BSE) under the scrip code 524516 and on the National Stock Exchange (NSE) under the symbol BACPHAR. The company’s management includes Tak Bhavana Tak as CEO/MD. Its auditors are Laxmikant Kabra & Co LLP. The company has reported Gross Sales of ₹0.00 Cr and Profit After Tax of ₹0.40 Cr for the latest financial year. 

B. Product Lines 

• Pharmaceutical products for human use (medicinal and botanical) 

• Herbal extracts from the Lote‑Parshuram plant facility 

• Drug intermediates for pharmaceutical manufacturing 

• Bulk drugs and pharmaceutical formulations 

• Contract manufacturing services for third‑party pharma companies 

C. Company Revenue Model 

• Primary revenue from manufacture and sale of pharmaceutical and herbal products. 

• Volume‑driven revenue based on quantity of drugs produced and sold.
  -Pricing determined by raw material costs and market demand for pharmaceutical products. 

• Revenue from contract manufacturing services for other pharmaceutical companies. 

• Income from drug intermediates and bulk drug formulations. 

• Focus on utilising the Lote‑Parshuram plant capacity to improve revenue generation. 

• Seasonal variations in demand for certain drugs affecting revenue patterns. 

• Government policy changes on drug pricing and licensing influencing revenue stability. 

D. Geographic Presence 

• Headquartered in Mumbai, Maharashtra, India. 

• Manufacturing facility located in Lote‑Parshuram, Maharashtra. 

• Operations focused on the domestic Indian pharmaceutical market. 

• Export facilities to select international markets (limited scale). 

• Serves customers across multiple states within India through distribution channels. 

E. Key Milestones 

• 1987 – Incorporated on May 8. 

• 2019 – Registered office and corporate office addresses established. 

• Listings on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). 

F. Industry Perspective

Bacil Pharma operates in the pharmaceutical industry. Globally, the pharmaceutical market was valued at approximately USD 1.6 trillion in 2025 and is projected to reach USD 2.3 trillion by 2030, growing at a CAGR of 7.1%. India is the 3rd largest pharmaceutical market by volume and 14th by value. The Indian pharmaceutical market was valued at USD 50 billion in 2024 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 15‑17%. India supplies over 50% of global demand for various vaccines and 40% of generic demand in key markets. Key drivers of demand include rising healthcare expenditure, increasing chronic disease prevalence, and government initiatives such as the Production Linked Incentive (PLI) scheme for pharmaceuticals. In recent years, India’s pharmaceutical exports have witnessed a boom, growing at a CAGR of around 10% to approximately USD 25‑30 billion annually. Challenges include stringent pricing regulations by the National Pharmaceutical Pricing Authority (NPPA), intense competition from both large multinationals and generic drug manufacturers, high regulatory compliance costs (including USFDA approvals), and the need for continuous research and development investments. The sector is also facing pressures from price control mechanisms under the Drug Price Control Order (DPCO), which caps prices of essential medicines, directly impacting profit margins for domestic producers like Bacil Pharma. The COVID-19 pandemic accelerated demand for certain pharmaceutical products, but the post-pandemic era has seen a moderation in demand coupled with increased raw material price volatility for active pharmaceutical ingredients sourced from China. 

Bacil Pharma Limited Stock Market Presence: Listings & Index Representation 

Bacil Pharma is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol BACPHAR and on the Bombay Stock Exchange (BSE) with the scrip code 524516. Its listing on both exchanges ensures that the Bacil Pharma share price is accessible to a wide investor base, encompassing both retail and institutional market participants. The ISIN for the company is INE711D01018. The company forms part of several benchmark indices that represent broad market segments. Bacil Pharma is included in the BSE SmallCap index and the BSE Healthcare index. On the NSE, the company is a constituent of the Nifty Microcap 250 index and the Nifty Total Market index. Being represented in these indices enhances the visibility and liquidity of the Bacil Pharma stock price, as index tracking funds may adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups within India’s pharmaceutical landscape. 

Bacil Pharma Limited Stock Performance and Share Price History 

The performance and share price history of Bacil Pharma Limited are influenced by a complex mix of operational challenges, regulatory actions, and speculative trading. A primary driver is the company’s fluctuating financial performance, as any positive news regarding new business ventures or improvement in profitability directly impacts the Bacil Pharma share price. Government policies regarding drug pricing and pharmaceutical manufacturing also play a critical role. For instance, when the company reports even modest profits, the Bacil Pharma share price often sees a sharp uptick. Conversely, delays in generating revenue or continued losses put pressure on the Bacil Pharma stock price. 

Another major factor is the company’s status as a micro‑cap pharmaceutical company with minimal operations, which can alter long‑term growth projections and influence the Bacil Pharma share price. Quarterly financial results, especially net profit and sales volume figures, cause immediate swings in the Bacil Pharma stock price. Additionally, broader market trends and even seasonal speculative interest in penny stocks contribute to volatility. Historically, the Bacil Pharma share price has shown extreme volatility, with sharp rallies during periods of positive announcements but also steep declines during phases of regulatory uncertainty and corporate inaction. 

The 52‑week high of the stock is largely dictated by sentiment shifts and external shocks. When the company reports progress in its manufacturing operations and reduction of losses, the Bacil Pharma share price tends to rally toward its 52‑week high; conversely, any regulatory action or failure to meet drug manufacturing standards can drive the Bacil Pharma share price down to a new low. The Bacil Pharma share price also hits its peak when management announces new product approvals, while ongoing losses and zero revenue from operations push the Bacil Pharma share price toward the yearly bottom. Broader market sell‑offs, such as during economic uncertainty, often drag the Bacil Pharma share price to multi‑month lows, even if fundamentals are improving from a low base. Conversely, a bullish pharmaceutical narrative can lift the Bacil Pharma share price to a new 52‑week high. Additionally, quarterly earnings misses have historically pressured the Bacil Pharma share price to test its lowest levels in a given year. 

The Bacil Pharma share price has exhibited significant volatility over the past decade, shaped by the company’s attempts to establish a foothold in the pharmaceutical sector. The Bacil Pharma share price recorded a positive movement from its 52‑week low of 26.69 to its 52‑week high of 61.80. The Bacil Pharma share price delivered a 1‑year return of approximately 35.33% as of recent months. The Bacil Pharma share price reached a 52‑week high of 61.80 and a 52‑week low of 26.69, indicating a wide trading range. The Bacil Pharma share price recorded a strong rally of 736.0% in 2024, followed by a sharp decline of 33.1% in 2025. The Bacil Pharma share price has shown a 1‑month return of approximately 15.21% and a 3‑month return of 37.49%. The Bacil Pharma share price has shown a 3‑year return of 121.10% and a 5‑year return of 74.33%. 

The Bacil Pharma stock price has been particularly responsive to corporate announcements regarding board meetings and changes in management. When the company reported a profit of just ₹0.04 crore for the quarter ended December 2025, the Bacil Pharma stock price showed a positive reaction from a very low base. The Bacil Pharma stock price has shown a pattern of strong positive momentum in years when the company’s revival prospects seemed achievable, such as in 2024, while periods of zero revenue generation have led to consolidation in the Bacil Pharma stock price. The Bacil Pharma stock price has shown a market capitalisation of approximately ₹79‑82 crore as of recent quarters. 

The Bacil Pharma share price reached its 52‑week high before declining, reflecting the volatility inherent in the micro‑cap pharmaceutical space. The Bacil Pharma share price has shown a year‑to‑date return of 60.1% as of April 2026. Comprehending these patterns in the Bacil Pharma share price is instrumental for investors seeking to contextualise long‑term performance trends, as the Bacil Pharma stock price movements illustrate how speculative interest, corporate action cycles, and investor expectations converge in market pricing for revival‑story pharmaceutical companies. 

The Bacil Pharma share price has shown distinct seasonal patterns over the past decade. The best performing period historically was the strong rally in 2024, which delivered a return of 736.0%, while the worst month was in 2025 with a decline of 33.1%. In terms of annual performance, the Bacil Pharma share price delivered its strongest annual return of 736.0% in 2024, followed by 148.4% in 2020 and 51.0% in 2021. The stock recorded negative annual returns in 2025 (-33.1%), 2023 (-31.7%), 2019 (-13.4%), and 2018. The Bacil Pharma share price has demonstrated that the stock tends to perform better in periods of high speculative interest in micro‑cap pharmaceutical turnarounds and positive drug sector sentiment. 

Bacil Pharma Limited Investor Relevance and Role in Portfolio 

Bacil Pharma holds a negligible position for portfolio investors who seek exposure to the pharmaceutical sector. The company’s ongoing efforts to generate revenue from its Lote‑Parshuram manufacturing facility align it very loosely with investment strategies that value turnaround stories in the pharmaceutical manufacturing space, but the limited revenue and zero gross sales make it unsuitable for serious portfolios. The Bacil Pharma share price often mirrors how speculative themes resonate with high‑risk investor portfolios. The Bacil Pharma share price is influenced by the company’s financial health and its ability to bring its manufacturing facility to full capacity, making it a speculative bet at best. 

Institutional stakeholders play an extremely limited role in Bacil Pharma’s ownership profile. Promoter holding had declined to 0.08% from 42.7% previously, and then further to 0.00% as of March 2026. Mutual funds hold 0.0% stake. Foreign Institutional Investors (FII) hold 0%, Domestic Institutional Investors (DII) hold 0%, and Insurance companies hold 0%. Retail public holds approximately 98.26% as of March 2026. Institutional stakeholders include no major fund houses, and the complete absence of institutional ownership reflects the highly speculative nature of this micro‑cap name. The top promoter was Gulecha Investment & Trading Co Pvt Ltd (10,800 shares / 0.08%). 

Based on data, Bacil Pharma exhibits varying levels of beta and volatility across different time horizons, though data remains limited for some periods due to the company’s micro‑cap nature. Based on data, the long‑term beta of Bacil Pharma stands at 0.45 from Bajaj Broking. On a daily basis, the intraday movement has shown high volatility, with daily price ranges of over 5‑10% being common. Moving to weekly observations, the weekly volatility is high but not consistently reported across all time frames due to the limited trading history. Based on data, the mean values for available periods align with the current price ranges, and standard deviations are elevated because of the stock’s micro‑cap nature. Overall, Bacil Pharma demonstrates significant variance in its returns compared to the Nifty and BSE indices, making it highly sensitive to company‑specific news and speculative trading rather than broad market movements. 

The Bacil Pharma stock price has shown periods of heightened responsiveness to sector‑specific news regarding drug approvals and regulatory changes. The Bacil Pharma share price’s beta reflects that the company’s micro‑cap status makes it subject to idiosyncratic factors rather than index‑driven moves. The Bacil Pharma share price has historically moved based on quarterly earnings announcements and management commentaries on plant utilisation. The Bacil Pharma share price has shown a 52‑week low of ₹26.69 and a 52‑week high of ₹61.80, reflecting the highly volatile nature of this speculative pharma name in the BSE Healthcare index. 

Bacil Pharma Limited Sectoral Relevance and Peer Positioning 

The sector relevance of Bacil Pharma is minimal due to its negligible operational activity. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Aurobindo Pharma Ltd, and Torrent Pharmaceuticals Ltd. However, Bacil Pharma is not a comparable player currently due to its micro‑cap status and absence of revenue from operations. Firms with parallels in micro‑cap scale are often referenced when evaluating relative performance, but the company’s financial metrics place it at the very bottom of the sector. 

In valuation terms, factors like the Bacil Pharma P/E ratio have shown extreme variations over different periods. The mean historical PE Ratio over the last few years has fluctuated wildly, from negative levels to as high as 115.69. The current P/E ratio stands at approximately 109‑115 times, trading at a 132‑141% premium to its peer median range of 46.11‑47.29 times. Periods when investors perceived improvements in profitability have corresponded with expansion in valuation multiples, whereas phases of zero revenue have seen valuation compression. The Bacil Pharma P/E ratio was extremely elevated in 2024 (736.0% return year) and remained high in 2025‑2026. 

Similarly, the Bacil Pharma EPS narrative has shown variation, but the company has reported zero or minimal profitability. The TTM EPS stands at approximately ₹0.51‑1.20 depending on the reporting period. Over the past ten years, the company has demonstrated inconsistent profitability, with net profit of ₹0.40 crore in the latest financial year against zero gross sales. Net income was ₹0.07 crore and then ₹0.04 crore in recent quarters. In 2019, net profit was at much lower levels; in 2020, 148.4% return; in 2021, 51.0% return; in 2024, a massive 736.0% return. The company’s net profit for the quarter ended December 2025 was just ₹0.04 crore (from revenue of ₹0.00 Cr). The EPS growth rate is not meaningful given the zero revenue base. Over five years, the company has seen average EPS decline, and the current TTM EPS of ₹0.51‑1.20 is still negligible compared to industry peers. The Bacil Pharma earnings have been positive in some quarters but only due to other income rather than operational revenue. The company reported Gross Sales of ₹0.00 Cr and Profit After Tax of ₹0.40 Cr in the latest FY, indicating that all profit came from non‑operating sources or accounting adjustments rather than core business activity. 

Bacil Pharma market cap has fluctuated between approximately ₹62 crore and ₹82 crore over the past few years. From fiscal year 2020 onwards, the market cap showed an increasing trend during periods of speculative interest, from around ₹30‑40 crore to a peak of approximately ₹82 crore in 2026. This increase mirrors the rally in the Bacil Pharma share price during periods of positive market sentiment. 

The Bacil Pharma earnings over the past ten years have been characterised by negligible or zero revenue. Net income has remained positive in some quarters (₹0.04‑0.67 crore) but from zero revenue, meaning the profit is derived from interest income, other income, or exceptional items rather than drug sales. For the quarter ended December 2025, revenue was ₹0.00 crore, operating expense was ₹0.03 crore, and net profit was ₹0.04 crore. In other quarters, revenue was ₹0.00 crore but net profit ranged from ₹0.01 crore to ₹0.67 crore. The Bacil Pharma share price has been influenced by these speculative valuation metrics. The Bacil Pharma stock price continues to be evaluated in the context of its recovery potential rather than current earnings power. The company’s zero gross sales remain a critical concern, and until it generates meaningful revenue from its pharmaceutical plant, the stock will continue to be driven by speculative sentiment rather than fundamentals. 

Summary 

Bacil Pharma is a micro‑cap pharmaceutical company listed on the BSE and NSE, where the Bacil Pharma share price reflects speculative sentiment around revival hopes, drug manufacturing potential, and pharma sector cycles. Its inclusion in the BSE SmallCap index supports limited visibility, while investor interest is driven by turnaround hopes rather than consistent revenue. Within the sector, the company’s competitive context and earnings dynamics provide limited perspective on its role in India’s pharmaceutical manufacturing landscape.